Esperion Launched Awareness Campaign for Nasal Diuretic
The nasal spray offers a new diuretic option for managing edema associated with heart failure and other conditions.
Updated on Oct. 8, 2026 in Heart Disease
Live Poll
Should government payment models prioritize cost-saving measures when determining specialist reimbursement?
Esperion has launched an awareness campaign for its FDA-approved bumetanide nasal spray, which serves as a short-term diuretic for managing fluid retention. This effort prepares healthcare providers for the transition to the CMS Ambulatory Specialty Model in early 2027.
Why it matters
The campaign aims to help integrated delivery networks manage edema more effectively before escalating to intravenous therapy, potentially improving patient access under the upcoming CMS value-based payment model.
A bioequivalence study of 68 healthy adults found no significant difference in maximum plasma concentration between the nasal spray and oral bumetanide. While the nasal version reaches peak concentration faster, researchers are still investigating its impact on pulmonary artery pressure.
The players
Esperion
A pharmaceutical company that focuses on developing therapies for cardiovascular diseases and metabolic disorders.
CMS
The federal agency that administers Medicare and develops innovative payment models for specialty care.
The details
Administered intranasally, the spray acts as a diuretic to reduce edema related to heart failure, hepatic, or renal disease by helping the body shed excess fluid. The awareness campaign provides guidance for nurse practitioners and physician assistants on using the spray as an alternative to existing therapies. Clinical participants reported potential side effects, including hypovolemia and headache.
Timeline
September 2025: The FDA approved the bumetanide nasal spray.
April 2026: Esperion acquired Corstasis Therapeutics.
September 30, 2026: Esperion announced the awareness campaign.
January 2027: The CMS Ambulatory Specialty Model begins.
Health Landscape
The adoption of new diuretic delivery methods reflects a broader shift toward optimizing outpatient care for heart failure management. This approach aligns with the upcoming CMS Ambulatory Specialty Model, which will evaluate cardiologist performance through Medicare Part B payment adjustments.
If you are managing fluid retention related to heart failure, talk to your doctor about whether an intranasal diuretic is a suitable alternative to your current medication. Keep in mind that this treatment is designed for short-term use and requires monitoring for potential side effects like dizziness.
The takeaway
Nasal diuretics offer a novel way to manage fluid buildup outside of a hospital setting. Always discuss any changes to your medication routine with your physician to ensure the therapy fits your specific health profile.
Further reading
For more on managing long-term heart conditions, visit our Heart Disease section.
More information
View the Esperion official news release for additional details on this therapy.
Source note: This article includes information reported by Ajmc.
Live Poll
Should government payment models prioritize cost-saving measures when determining specialist reimbursement?
